STAMPEDE — Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) - Abiraterone Comparison

Phase 3 · 2017 · Prostate Cancer

Design

Multi-arm, multi-stage platform trial; the abiraterone comparison added abiraterone acetate plus prednisolone to standard androgen-deprivation therapy.

Population

Men starting long-term androgen-deprivation therapy for high-risk locally advanced or metastatic hormone-naive prostate cancer.

Primary Endpoint

overall survival (OS)

Key Result

3-year OS 83% vs 76% (OS HR 0.63); failure-free survival HR 0.29 favoring added abiraterone.

Guideline Impact

NCCN category 1 for abiraterone in metastatic castration-sensitive prostate cancer